Title : A novel mechanism of irinotecan targeting MDM2 and Bcl-xL.

Pub. Date : 2019 Jun 25

PMID : 31056264






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In this study, we present a new mechanism of Irinotecan which inhibits the activities of MDM2, an E3 ligase of tumour suppressor p53, and Bcl-xL, an anti-apoptotic protein, through direct binding. Irinotecan tumor protein p53 Homo sapiens
2 We further showed that Irinotecan increased the amount of p53 only in the presence of MDM2 and inhibited the physical interaction of Bcl-xL with Bim, a core pro-apoptotic protein. Irinotecan tumor protein p53 Homo sapiens
3 Collectively, we suggest a new mechanism of action for Irinotecan as a dual target inhibitor of MDM2 and Bcl-xL facilitating the anticancer activities mediated by p53 and Bcl-xL interaction partners. Irinotecan tumor protein p53 Homo sapiens